CALGARY, Alberta, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Inhibitors of bromodomain and extraterminal proteins for treating multiple human diseases”, in the peer-reviewed Medicinal Research Reviews.
The publication can be viewed using the following LINK.
“We assessed the current understanding of transcriptional mechanisms of BET inhibition to explain why BD2selective compounds, like apabetalone, are showing a unique clinical response with fewer adverse events, making it appropriate for the treatment of chronic disease states including those explored in our development program,” said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development at Resverlogix, and an author of the review. “Furthermore, this review – highlighting our leadership position in this research space – addresses the mechanisms by which apabetalone and other BET inhibitors can improve the maladaptive gene expression that underlies numerous human diseases.”
Publication Highlights include:
- A review of the role BET proteins play in enhancer and super-enhancer formation, and how that may drive multiple disease states
- A discussion of approaches to targeting BET proteins and the importance of bromodomain-selective binding among these compounds
- An overview of research into BET inhibitors, such as apabetalone, as therapeutics for chronic disease, including: cardiovascular, autoimmune, and metabolic diseases
- Emerging evidence for the improved safety and tolerability of BD2 selective compounds, including from the largest BETi trial to date, BETonMACE
Publication Background and Conclusions:
BET inhibitors represent a new paradigm in drug development due to their novel mechanism of action with potential to treat a broad spectrum of human diseases. This review details how targeted BET inhibitors do not simply reduce expression of every gene with BET-dependent transcription, but rather these therapeutic compounds act in concert with transcriptional machinery to target those genes that are upregulated or overexpressed by disease. The authors conclude that the research into selective BET inhibitors shows significant promise, writing: “Focused development of BDselective compounds is certain to alter and expand the clinical landscape for years to come.”
G1945V